Domino liver transplant from a donor with maple syrup urine disease into a recipient with phenylketonuria.
Classical phenylketonuria (PKU)
Domino liver transplantation
Maple syrup urine disease
Maternal PKU
PAH, phenylalanine hydroxylase
PKU, phenylketonuria
Phe, phenylalanine
Trp, Tryptophan
Tyr, tyrosine
Journal
Molecular genetics and metabolism reports
ISSN: 2214-4269
Titre abrégé: Mol Genet Metab Rep
Pays: United States
ID NLM: 101624422
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
14
01
2022
revised:
28
03
2022
accepted:
02
04
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
Classical phenylketonuria (PKU) presents a unique challenge for women of child-bearing age. In the context of pregnancy, poorly controlled hyperphenylalaninemia can result in a devastating constellation of outcomes for the baby referred to as the maternal PKU Syndrome. We present the case of a woman with classical PKU unable to maintain a restricted diet and refractory to pharmacological therapies. She elected to undergo a domino liver transplant, receiving an organ from a donor with classical branched chain ketoacid dehydrogenase deficiency (maple syrup urine disease). Plasma phenylalanine concentrations normalized within a few days after transplant and remained so on an unrestricted diet during the first year of follow-up. The patient reports subjective improvements in mood, energy level, and overall quality of life. In the appropriate clinical setting, liver transplant should be considered to provide metabolic stability for PKU patients, particularly women of childbearing age.
Identifiants
pubmed: 35782613
doi: 10.1016/j.ymgmr.2022.100866
pii: S2214-4269(22)00026-X
pmc: PMC9248231
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100866Informations de copyright
© 2022 Published by Elsevier Inc.
Déclaration de conflit d'intérêts
The authors of this manuscript have no conflicts of interest to disclose. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Références
Mol Genet Metab Rep. 2018 Jul 11;16:39-45
pubmed: 30069431
Mol Genet Metab. 1999 Aug;67(4):308-16
pubmed: 10444341
Am J Gastroenterol. 2021 Mar 1;116(3):560-567
pubmed: 33470611
N Engl J Med. 1980 Nov 20;303(21):1202-8
pubmed: 7421947
JAMA. 2000 Feb 9;283(6):756-62
pubmed: 10683054
Am J Obstet Gynecol. 1989 Nov;161(5):1102-5
pubmed: 2686439
Am J Clin Nutr. 2012 Feb;95(2):374-82
pubmed: 22205310
Clin Biochem. 1987 Jun;20(3):149-56
pubmed: 3308176
Transplantation. 2003 Sep 15;76(5):827-32
pubmed: 14501862
Lancet. 2010 Oct 23;376(9750):1417-27
pubmed: 20971365
Clin Transplant. 2019 Nov;33(11):e13721
pubmed: 31556146
Mol Genet Metab Rep. 2015 Dec 29;6:8-12
pubmed: 27014571
Liver Transpl. 2018 Jun;24(6):769-778
pubmed: 29655314
N Engl J Med. 1993 Jul 29;329(5):363
pubmed: 8321274
JIMD Rep. 2019 Jun 19;48(1):83-89
pubmed: 31392117
J Matern Fetal Neonatal Med. 2021 Oct;34(19):3269-3276
pubmed: 31635500
Am J Obstet Gynecol. 1978 Oct 1;132(3):340-1
pubmed: 360844
BMC Pregnancy Childbirth. 2021 Sep 16;21(1):627
pubmed: 34530745
Mol Genet Metab. 2017 Mar;120(3):190-197
pubmed: 28162992
Genet Med. 2014 Feb;16(2):188-200
pubmed: 24385074
Mol Genet Metab. 2014 Apr;111(4):418-27
pubmed: 24495602
Pediatrics. 2003 Dec;112(6 Pt 2):1537-43
pubmed: 14654661
Mol Genet Metab. 2012 Apr;105(4):559-65
pubmed: 22300847
Pediatr Transplant. 2021 Dec;25(8):e14114
pubmed: 34448327
J Pediatr. 2012 May;160(5):820-6.e3
pubmed: 22192813
Genet Med. 2002 Mar-Apr;4(2):84-9
pubmed: 11882785
Liver Transpl. 2020 Apr;26(4):564-581
pubmed: 31950556
Curr Med Res Opin. 2019 Apr;35(4):647-651
pubmed: 30247930
Mol Genet Metab. 2021 Apr 7;:
pubmed: 33846068